



SEATTLE GENETICS AND EXCELERA

Partnership to promote improved
access and patient outcomes

SEATTLE GENETICS IS PARTNERING WITH EXCELERA TO PROVIDE
ACCESS TO SEATTLE GENETICS' SPECIALTY ONCOLOGY PRODUCTS



Seattle Genetics recognizes that readily available access to oncology medications close to the prescriber is important for appropriate disease management. Our goal is to deliver a consistent patient experience regardless of the distribution network for oral oncology medications.



Seattle Genetics has engaged with Excelera to provide access to Seattle Genetics' specialty oncology products, education, and resources to integrated delivery networks (IDNs) in an effort to improve overall patient experience and outcomes. Excelera also provides IDNs with solutions to build, operationalize, and optimize IDN specialty pharmacies (SPs).

Seattle Genetics is committed to providing an enhanced, positive, and seamless experience for patients taking our oral oncology therapies.



BENEFITS OF SEATTLE GENETICS' ENGAGEMENT WITH EXCELERA

Key features of Excelera include

- Comprehensive end-to-end IT/data platform that addresses the needs of the pharmaceutical industry to allow participation in limited distribution drug access programs
- Dashboards to provide visibility into each IDN SP performance and compare against the Excelera network average
- Ad hoc reporting that creates actionable reports and insights
- Product and disease state training to provide a high level of provider and patient counseling
- Access to patient service programs and resources to assist patients
- Ability to dispense a limited distribution drug on Day 1 of a product launch
- Management of administrative and IT set-up, allowing the IDNs to focus on taking care of patients

SEATTLE GENETICS CRITERIA FOR SPECIALTY PHARMACY ACCREDITATION USING EXCELERA

If you wish to partner with Excelera, please ensure the following criteria are met

- SP provides proof of ownership, demonstrating that it is a subsidiary of a hospital or the parent company of a hospital or IDN
- The hospital, hospital system, or IDN must employ or give prescribing privileges to at least one oncologist who treats patients with cancer
- SP may only purchase approved Seattle Genetics' oncolytics through Seattle Genetics' authorized specialty distributors (Authorized Distributors)
- SP will purchase approved Seattle Genetics' oncolytics only for dispensing to patients treated by prescribers within the hospital, hospital system, or IDN. SP warrants that it will not dispense, sell, or otherwise provide approved Seattle Genetics' oncolytics to any entity not part of the hospital, hospital system, or IDN
- SP shall provide Excelera with required Seattle Genetics' data on a daily or weekly basis
- SP shall utilize Seattle Genetics' Patient Service Program when SP anticipates challenges with patient financial assistance or insurance coverage
- SP agrees to transfer prescription to Seattle Genetics' Patient Service Program or directly to a Seattle Genetics network SP when unable or unwilling to dispense a prescription
- SP agrees to report all adverse events, product quality issues, and other requirements as mandated by Seattle Genetics



Contact us for additional information by emailing us at trade@seagen.com

